Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

Recruiting

• Conditions: Immunotherapy; Colon Cancer

• Registration Number: NCT06573424
• Lead Sponsor: fan li

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-15
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - 18-70 years old<br><br> - Patients with mss colorectal cancer who have been confirmed by pathology and have<br> relapsed or failed multiline therapy<br><br> - Patients who have been treated with anlotinib monotherapy(12 mg qd, d1-14; 21 days<br> per cycle) or anlotinib(12 mg qd, d1-14; 21 days per cycle)+ tislelizumab(200 mg,<br> once every 3 weeks)<br><br> - the presence of at least one measurable target lesion according to the Response<br> Evaluation Criteria in Solid Tumors (RECIST) version 1.1<br><br>Exclusion Criteria:<br><br> - Patients with other malignant tumors<br><br> - Prior treatment with antirotinib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or<br> anti-CTLA-4 antibodies or any other antibody or drug that specifically targets T<br> cell co-stimulation or checkpoint pathways<br><br> - Follow-up was less than 30 days

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS

Secondary Outcome Measures

Name	Time	Method
OS;Multiomic molecular characterization of the response to combination immunotherapy